Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

The rights agreement, often referred to as a "poison pill," was established in response to recent accumulations of Pliant’s common stock. It aims to ensure that the Board has sufficient time to ...

The rights agreement, often referred to as a "poison pill," was established in response to recent accumulations of Pliant’s common stock. It aims to ensure that the Board has sufficient time to ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

I spent my childhood afraid of taking a wrong step, always desperate to remain in my mother’s good graces. I did whatever I ...